NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether CVRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 7, 2025, CVRx announced weaker than expected preliminary first quarter results. In the Company’s earnings press release, CVRx’s President and Chief Executive Officer said that “many of [the Company’s] newer sales representatives are still in the early stages of development.”
On this news, CVRx’s stock price fell $5.34 per share, or 46.3%, to close at $6.20 per share on April 8, 2025.
Then, on May 8, 2025, CVRx announced weak first quarter results and lowered its full year revenue guidance. During the related earnings call, CEO Hykes said that recent salesforce changes at the Company were “more significant than initially anticipated and resulted in 25% of our current territory managers being hired between December and March.”
On this news, CVRx’s stock price fell $3.01 per share, or 38.7%, to close at $4.77 per share on May 9, 2025.
Then, on August 6, 2026, CVRx lowered its full-year revenue guidance to $58 million-$60 million from $63 million-$67 million. Management stated: "This rapid pace of hiring has strained our onboarding and training processes and the ability of our area sales directors to spend the time necessary to accelerate these new team members up the productivity curve." Management further stated: "The scale of the turnover, the slower pace of the territory manager productivity ramp, and the concentration of these new hires in a subset of our regions are the primary factors behind today's guidance update." Management also stated that slightly less than half of CVRx's regions, those with the highest turnover and least-tenured leaders, were experiencing negative year-to-date implant growth. CVRx also attributed its revised outlook in part to a prolonged challenge with one of its largest Medicare Advantage payers. The Company further disclosed that it received a Department of Justice civil investigative demand in May 2026 concerning certain sales and marketing practices.
On this news, CVRx’s stock price fell $3.55 per share, or 59.76%, to close at $2.39 per share on August 7, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
